Jefferies downgraded IGM Biosciences (IGMS) to Hold from Buy with a price target of $2, down from $48, after the company discontinued all clinical development of drugs in its autoimmune franchise ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. ("IGM" or the "Company") (NASDAQ:IGMS). Such investors are ...

SEC Filings provided by EDGAR Online, Inc.

IGM Financial Inc. (TSE:IGM – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the six research firms that are presently covering the stock, MarketBeat reports.

iShares Expanded Tech Sector ETF Price Performance Shares of IGM stock opened at $107.05 on Thursday. The stock’s 50-day moving average is $103.00 and its two-hundred day moving average is $97. ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Douglas Tsao, an analyst from H.C. Wainwright, reiterated the Buy rating on Coherus Biosciences (CHRS – Research Report). The associated price target remains the same with $7.00. Douglas Tsao ...

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the late ...